ArticleCancer gene therapy2026
HOXC11 promotes head and neck squamous cell carcinomas (HNSCC) progression by regulating SPHK1 through the Wnt signaling pathway.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of potential targets in Head and neck squamous cell carcinomas (HNSCC) through molecular and mechanism analyses is crucial for understanding and treating this disease. This study utilized rigorous methods, including cell lines (FaDu and SCC-15) and a xenograft tumor model. Transfections were conducted using the Lipofectamine 2000 kit, and the evaluation of HOXC11, SPHK1, apoptosis-related protein, and the Wnt signaling pathway was carried out using qPCR and WB methods. The cell proliferation, migration, invasion, and apoptosis were comprehensively evaluated using colony formation, Transwell, wound healing, and flow cytometry, respectively. HOXC11 and SPHK1 are highly expressed in HNSCC and might be involved in the Wnt signaling pathway. HOXC11 promoted cell proliferation, migration, and invasion, inhibiting apoptosis in HNSCC. Silencing SPHK1 inhibited cell progression and dysregulated the Wnt signaling pathway in HNSCC. Overexpressed SPHK1 reversed the functions of sh-HOXC11 in regulating cell progression and the Wnt signaling pathway. HOXC11 promotes HNSCC progression by regulating SPHK1 through the Wnt signaling pathway. Silencing HOXC11 inhibited the tumor growth of HNSCC. Our study demonstrates that HOXC11 promotes HNSCC progression by regulating SPHK1 through the Wnt/β-catenin signaling pathway, identifying a previously unrecognized regulatory axis in HNSCC.
Indexed as
Identifiers
42502105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.